Overview

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of alb-interferon in adults with genotype 2 or 3 chronic hepatitis
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Collaborator:
Human Genome Sciences Inc.
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons